Bio-Connect

InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar)

SIM0004
Bio X Cell
ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Bio X Cell
  • Product Name
    InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar)
  • Delivery Days Customer
    7
  • Applications
    Flow Cytometry, Western Blot, ELISA, Neutralisation/Blocking
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    Ipilimumab
  • Concentration
    4-11 mg/ml
  • Estimated Purity
    >95%
  • Host
    Human
  • Isotype
    IgG1
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Watanabe T, Ishino T, Ueda Y, et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. 2023,114(5):1859-1870. doi: 10.1111/cas.15756
    Read this paper
  • Crupi MJF, Taha Z, Janssen TJA, et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol. 2022,13:1029269. doi: 10.3389/fimmu.2022.1029269
    Read this paper
  • Qiu H, Zmina PM, Huang AY, et al. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. Cancer Lett. 2018,434:144-151. doi: 10.1016/j.canlet.2018.07.024
    Read this paper